GAITHERSBURG, Md., March 3, 2014 /PRNewswire/ -- GenVec, Inc. (NASDAQ:GNVC) announced today that the Company will participate in the 26th Annual ROTH Conference being held March 9-12, 2014 in Dana Point, California. Douglas Swirsky, President and CEO of GenVec, will present a company overview on Monday, March 10, 2014 at 3:00 pm Pacific Daylight Time.
A webcast of Mr. Swirsky's presentation will be available both live and on replay. The presentation will be available via webcast athttp://wsw.com/webcast/roth28/GNVC. A replay will also be available for 90 days following the live presentation. The live webcast and subsequent archived replay of GenVec's presentation will also be accessible via the Investors and Media section of the Company's web site at http://ir.genvec.com under "Events & Presentations."
GenVec is a biopharmaceutical company working with leading companies and organizations such as Novartis and the U.S. Government to leverage GenVec's proprietary gene-delivery technologies to address the prevention and treatment of significant health concerns. GenVec's lead program, in the field of regenerative medicine, is licensed to Novartis for the development of novel treatments for hearing loss and balance disorders. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
SOURCE GenVec, Inc.